Across TCGA pan-cancer cohorts, ZNF134 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF134 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF134 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF134 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where ZNF134 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.882	0.662	.006	24	view →
GBM	DFS	Median	All	0.641	0.922	.002	7	view →
LUAD	DFS	Median	II,III,IV	0.135	0.786	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZNF134 tumor-vs-normal RNA expression · all ZNF134 data types